GB201709417D0 - Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer - Google Patents

Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer

Info

Publication number
GB201709417D0
GB201709417D0 GBGB1709417.8A GB201709417A GB201709417D0 GB 201709417 D0 GB201709417 D0 GB 201709417D0 GB 201709417 A GB201709417 A GB 201709417A GB 201709417 D0 GB201709417 D0 GB 201709417D0
Authority
GB
United Kingdom
Prior art keywords
inhibitors
methods
treating cancer
dependent kinase
cyclin dependent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1709417.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Breast Cancer Now
Institute of Cancer Research
Original Assignee
Breast Cancer Now
Institute of Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breast Cancer Now, Institute of Cancer Research filed Critical Breast Cancer Now
Priority to GBGB1709417.8A priority Critical patent/GB201709417D0/en
Publication of GB201709417D0 publication Critical patent/GB201709417D0/en
Priority to PCT/EP2018/065349 priority patent/WO2018228990A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
GBGB1709417.8A 2017-06-14 2017-06-14 Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer Ceased GB201709417D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1709417.8A GB201709417D0 (en) 2017-06-14 2017-06-14 Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer
PCT/EP2018/065349 WO2018228990A1 (en) 2017-06-14 2018-06-11 Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709417.8A GB201709417D0 (en) 2017-06-14 2017-06-14 Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer

Publications (1)

Publication Number Publication Date
GB201709417D0 true GB201709417D0 (en) 2017-07-26

Family

ID=59358399

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1709417.8A Ceased GB201709417D0 (en) 2017-06-14 2017-06-14 Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer

Country Status (2)

Country Link
GB (1) GB201709417D0 (en)
WO (1) WO2018228990A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020013915A2 (en) 2018-01-08 2020-12-01 G1 Therapeutics, Inc. dosing regimen for release, and, method to treat cancer dependent on cdk4 / 6 replication in a human
CN109371128A (en) * 2018-10-22 2019-02-22 广东省人民医院(广东省医学科学院) A kind of primer and kit and application for detecting CREBBP gene mutation site

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2880448B1 (en) * 2012-08-03 2022-06-29 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
WO2016042164A1 (en) * 2014-09-19 2016-03-24 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Unidv. Trinity Of Queen Elizabeth, Near Dublin A method of predicting risk of recurrence of cancer

Also Published As

Publication number Publication date
WO2018228990A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
IL277665A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL272948B1 (en) Enpp1 inhibitors and their use for the treatment of cancer
IL255189B2 (en) A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
IL261721A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
IL284199A (en) Csf1r inhibitors for use in treating cancer
IL284324A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
EP3464643A4 (en) Use of ezh2 inhibitors for treating cancer
IL284326A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL266182A (en) Farnesyltransferase inhibitors for use in methods of treating cancer
IL269710A (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
IL259862B (en) Inhibitors of bruton's tyrosine kinase and methods of their use
EP3576766A4 (en) Cyclin g1 inhibitors and related methods of treating cancer
GB201709417D0 (en) Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer
EP3654967A4 (en) Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer
EP3774799C0 (en) Nek6 kinase inhibitors useful for the treatment of solid tumors
GB201709076D0 (en) Parp inhibitors for use in methods of treating cancer
PT3601296T (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
GB201621472D0 (en) Inhibitors of ataxia-tellangiectasia mutated and rad3-related protein kinase (ATR) for use in methods of treating cancer
GB201600388D0 (en) Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (ATR) for use in methods of treating cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)